Search Results - "Newton, Robert C"

Clinicogenomic Analysis of FGFR2 -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib by Silverman, Ian M, Hollebecque, Antoine, Friboulet, Luc, Owens, Sherry, Newton, Robert C, Zhen, Huiling, Féliz, Luis, Zecchetto, Camilla, Melisi, Davide, Burn, Timothy C

“…Pemigatinib, a selective FGFR1-3 inhibitor, has demonstrated antitumor activity in FIGHT-202, a phase II study in patients with cholangiocarcinoma harboring…”
Get more information

Developing c-MET pathway inhibitors for cancer therapy: progress and challenges by Liu, Xiangdong, Newton, Robert C, Scherle, Peggy A

“…Successfully developed target-based therapies have significantly changed cancer treatment. Among many targets, the c-MET receptor tyrosine kinase and its…”
Get full text

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity by Liu, Xiangdong, Shin, Niu, Koblish, Holly K., Yang, Gengjie, Wang, Qian, Wang, Kathy, Leffet, Lynn, Hansbury, Michael J., Thomas, Beth, Rupar, Mark, Waeltz, Paul, Bowman, Kevin J., Polam, Padmaja, Sparks, Richard B., Yue, Eddy W., Li, Yanlong, Wynn, Richard, Fridman, Jordan S., Burn, Timothy C., Combs, Andrew P., Newton, Robert C., Scherle, Peggy A.

“…Indoleamine 2,3-dioxygenase-1 (IDO1; IDO) mediates oxidative cleavage of tryptophan, an amino acid essential for cell proliferation and survival. IDO1…”
Get full text

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050 by Fridman, Jordan S, Scherle, Peggy A, Collins, Robert, Burn, Timothy C, Li, Yanlong, Li, Jun, Covington, Maryanne B, Thomas, Beth, Collier, Paul, Favata, Margaret F, Wen, Xiaoming, Shi, Jack, McGee, Ryan, Haley, Patrick J, Shepard, Stacey, Rodgers, James D, Yeleswaram, Swamy, Hollis, Greg, Newton, Robert C, Metcalf, Brian, Friedman, Steven M, Vaddi, Kris

“…Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases such as rheumatoid arthritis…”
Get full text

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma by Gibney, Geoffrey T, Hamid, Omid, Lutzky, Jose, Olszanski, Anthony J, Mitchell, Tara C, Gajewski, Thomas F, Chmielowski, Bartosz, Hanks, Brent A, Zhao, Yufan, Newton, Robert C, Maleski, Janet, Leopold, Lance, Weber, Jeffrey S

“…Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. We present phase 1 results from a phase 1/2 clinical…”
Get full text

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer by Zhou, Bin-Bing S., Peyton, Michael, He, Biao, Liu, Changnian, Girard, Luc, Caudler, Eian, Lo, Yvonne, Baribaud, Frederic, Mikami, Iwao, Reguart, Noemi, Yang, Gengjie, Li, Yanlong, Yao, Wenqing, Vaddi, Kris, Gazdar, Adi F., Friedman, Steven M., Jablons, David M., Newton, Robert C., Fridman, Jordan S., Minna, John D., Scherle, Peggy A.

“…We describe here the existence of a heregulin-HER3 autocrine loop, and the contribution of heregulin-dependent, HER2-mediated HER3 activation to gefitinib…”
Get full text

Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation by Fridman, Jordan S., Scherle, Peggy A., Collins, Robert, Burn, Timothy, Neilan, Claire L., Hertel, Denise, Contel, Nancy, Haley, Patrick, Thomas, Beth, Shi, Jack, Collier, Paul, Rodgers, James D., Shepard, Stacey, Metcalf, Brian, Hollis, Gregory, Newton, Robert C., Yeleswaram, Swamy, Friedman, Steven M., Vaddi, Kris

“…JAKs are required for signaling initiated by several cytokines (e.g., IL-4, IL-12, IL-23, thymic stromal lymphopoietin (TSLP), and IFNγ) implicated in the…”
Get full text

Quartz solubility in H2O-NaCl and H2O-CO2 solutions at deep crust-upper mantle pressures and temperatures: 2–15 kbar and 500–900°C by Newton, Robert C, Manning, Craig E

Get full text

Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer by Fridman, Jordan S, Caulder, Eian, Hansbury, Michael, Liu, Xiangdong, Yang, Genjie, Wang, Qian, Lo, Yvonne, Zhou, Bin-Bing, Pan, Maxwell, Thomas, Sufi M, Grandis, Jennifer R, Zhuo, Jincong, Yao, Wenqing, Newton, Robert C, Friedman, Steven M, Scherle, Peggy A, Vaddi, Kris

“…Purpose: ErbB receptor signaling pathways are important regulators of cell fate, and their dysregulation, through (epi)genetic alterations, plays an etiologic…”
Get full text

Aggrecan Protects Cartilage Collagen from Proteolytic Cleavage by Pratta, Michael A., Yao, Wenqing, Decicco, Carl, Tortorella, Micky D., Liu, Riu-Qin, Copeland, Robert A., Magolda, Ronald, Newton, Robert C., Trzaskos, James M., Arner, Elizabeth C.

“…The matrix components responsible for cartilage mechanical properties, type II collagen and aggrecan, are degraded in osteoarthritis through proteolytic…”
Get full text

Discovery and Pharmacological Characterization of a Novel Rodent-Active CCR2 Antagonist, INCB3344 by Brodmerkel, Carrie M, Huber, Reid, Covington, Maryanne, Diamond, Sharon, Hall, Leslie, Collins, Robert, Leffet, Lynn, Gallagher, Karen, Feldman, Patricia, Collier, Paul, Stow, Mark, Gu, Xiaomei, Baribaud, Frederic, Shin, Niu, Thomas, Beth, Burn, Tim, Hollis, Greg, Yeleswaram, Swamy, Solomon, Kim, Friedman, Steve, Wang, Anlai, Xue, Chu Biao, Newton, Robert C, Scherle, Peggy, Vaddi, Kris

“…This report describes the characterization of INCB3344, a novel, potent and selective small molecule antagonist of the mouse CCR2 receptor. The lack of rodent…”
Get full text

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies by Beatty, Gregory L, O'Dwyer, Peter J, Clark, Jason, Shi, Jack G, Bowman, Kevin J, Scherle, Peggy A, Newton, Robert C, Schaub, Richard, Maleski, Janet, Leopold, Lance, Gajewski, Thomas F

“…Indoleamine 2,3-dioxygenase-1 (IDO1) catalyzes the degradation of tryptophan to N-formyl-kynurenine. Overexpressed in many solid malignancies, IDO1 can promote…”
Get full text

A Geo-Experimental Diagram for Garnet Amphibolite and Its Bearing on the Origin of Continents by Newton, Robert C.

“…Dehydration (fluid-absent) melting of garnetiferous amphibolite is now widely believed to have given rise to the tonalite-trondhjemite-granodiorite (TTG) suite…”
Get full text

Pharmacological characterization of INCB3344, a small molecule antagonist of human CCR2 by Shin, Niu, Baribaud, Frédéric, Wang, Kathy, Yang, Genjie, Wynn, Rich, Covington, Maryanne B., Feldman, Patricia, Gallagher, Karen B., Leffet, Lynn M., Lo, Yvonne Y., Wang, Anlai, Xue, Chu-Biao, Newton, Robert C., Scherle, Peggy A.

“…The chemokine receptor 2 (CCR2) directs migration of monocytes and has been proposed to be a drug target for chronic inflammatory diseases. INCB3344 was first…”
Get full text

Incipient charnockite: Characterization at the type localities by Newton, Robert C., Tsunogae, Toshiaki

“…•Kabbal-type metasomatism is related to hornblende breakdown and loss of FeO, CaO, and H2O.•Ponmudi-type alteration is related to loss of FeO and MgO, and…”
Get full text

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia by Eghtedar, Alireza, Verstovsek, Srdan, Estrov, Zeev, Burger, Jan, Cortes, Jorge, Bivins, Carol, Faderl, Stefan, Ferrajoli, Alessandra, Borthakur, Gautam, George, Solly, Scherle, Peggy A., Newton, Robert C., Kantarjian, Hagop M., Ravandi, Farhad

“…We conducted a phase 2 study of ruxolitinib in patients with relapsed/refractory leukemias. Patients with acceptable performance status (0-2), adequate organ…”
Get full text

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer by Kristeleit, Rebecca, Davidenko, Irina, Shirinkin, Vadim, El-Khouly, Fatima, Bondarenko, Igor, Goodheart, Michael J., Gorbunova, Vera, Penning, Carol A., Shi, Jack G., Liu, Xiangdong, Newton, Robert C., Zhao, Yufan, Maleski, Janet, Leopold, Lance, Schilder, Russell J.

“…Indoleamine 2,3-dioxygenase-1 (IDO1) is a key regulator of immune tolerance in ovarian cancer. This study investigated efficacy and safety of the IDO1 enzyme…”
Get full text

Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab by Liu, Xiangdong, Fridman, Jordan S., Wang, Qian, Caulder, Eian, Yang, Gengjie, Covington, Maryanne, Liu, Changnian, Marando, Cindy, Zhuo, Jincong, Li, Yanlong, Yao, Wenqing, Vaddi, Kris, Newton, Robert C., Scherle, Peggy A., Friedman, Steven M.

“…The HER-2 receptor tyrosine kinase is an important regulator of cell proliferation and survival, and it is a clinically validated target of therapeutic…”
Get full text

Streaming of saline fluids through Archean crust: Another view of charnockite-granite relations in southern India by Newton, Robert C., Ya. Aranovich, Leonid, Touret, Jacques L.R.

“…The complementary roles of granites and rocks of the granulite facies have long been a key issue in models of the evolution of the continental crust…”
Get full text

A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3 by XIANGDONG LIU, QIAN WANG, BOER, Jason, DIAMOND, Sharon, CHUNHONG HE, MEIZHONG XU, JINCONG ZHUO, WENQING YAO, NEWTON, Robert C, SCHERLE, Peggy A, GENGJIE YANG, MARANDO, Cindy, KOBLISH, Holly K, HALL, Leslie M, FRIDMAN, Jordan S, BEHSHAD, Elham, WYNN, Richard, YU LI

“…The c-MET receptor tyrosine kinase plays important roles in the formation, progression, and dissemination of human cancer and presents an attractive…”
Get full text